← All trials
NCT03118570
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 11, 2017
- Primary completion
- Oct 1, 2019
- Completion date
- Nov 12, 2020
- First posted
- Apr 18, 2017
- Last posted
- Jul 5, 2023
- Enrollment
- 112
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ultragenyx Inc.Lead sponsor
- Mereo BioPharmaCollaborator
- Mereo BioPharmaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.